Sign In
Buy ZTS
$77.59
+1.20 (+1.57%)
At Close: Jun 03, 2026
Zoetis' (ZTS) Companion Animal Products to Boost Revenues
12:47pm, Wednesday, 23'rd Aug 2023
Zoetis' (ZTS) revenues are expected to boost the pet care and livestock product sales in the quarters ahead. Disease outbreaks and potential supply challenges hurt prospects.
Our Top 10 Picks For Dividend Growth Stocks - August 2023
09:30am, Saturday, 19'th Aug 2023
This monthly series of articles focuses on DGI stocks that are likely to provide a high rate of dividend growth rather than a high current yield. We use our proprietary models to rate quantitatively a
USNA or ZTS: Which Is the Better Value Stock Right Now?
01:00pm, Thursday, 10'th Aug 2023
Investors interested in stocks from the Medical - Drugs sector have probably already heard of USANA Health Sciences (USNA) and Zoetis (ZTS). But which of these two stocks is more attractive to value i
Zoetis CEO Kristin Peck on Q2 earnings results, state of animal health care
12:35pm, Tuesday, 08'th Aug 2023
Kristin Peck, Zoetis CEO, joins 'Squawk on the Street' to discuss what the company's guidance was largely driven by, the most important aspect of Zoetis' business, and how new GLP-1 drugs could play i
Zoetis Inc. (ZTS) Q22023 Earnings Call Transcript
12:22pm, Tuesday, 08'th Aug 2023
Zoetis Inc. (NYSE:ZTS ) Q22023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Steve Frank - Vice President of Investor Relations Kristin Peck - Chief Executive Officer Wetteny
Zoetis (ZTS) Reports Q2 Earnings: What Key Metrics Have to Say
12:10pm, Tuesday, 08'th Aug 2023
The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates a
Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates
12:10pm, Tuesday, 08'th Aug 2023
Zoetis (ZTS) reports better-than-expected second-quarter 2023 results, beating both earnings and revenue estimates, primarily driven by the sales of its key dermatology products.
Zoetis (ZTS) Beats Q2 Earnings and Revenue Estimates
09:56am, Tuesday, 08'th Aug 2023
Zoetis (ZTS) came out with quarterly earnings of $1.41 per share, beating the Zacks Consensus Estimate of $1.32 per share. This compares to earnings of $1.20 per share a year ago.
My Top 15 High Growth Dividend Stocks For August 2023
11:13pm, Saturday, 05'th Aug 2023
The watchlist from July posted a gain of 5.36% last month, outperforming the SPDR S&P 500 Trust ETF and Vanguard's Dividend Appreciation ETF. The top 15 dividend growth stocks for August offer an aver
Rising Dividend Make Zoetis a Doggone Winner
07:41am, Thursday, 03'rd Aug 2023
When Zoetis Inc. NYSE: ZTS reports second-quarter financials next week, the market will be expecting its best revenue growth in a year and a 9% jump in profits. If history repeats, the results will be
2 Healthcare Stocks That Could Make You Richer
09:30am, Saturday, 29'th Jul 2023
As a producer of medicines for animals, Zoetis benefits from increased spending on pets. Thanks to a strong product line, Eli Lilly briefly ranked as the biggest pharma company this year.
Zoetis (ZTS) Moves 6.9% Higher: Will This Strength Last?
04:50am, Monday, 24'th Jul 2023
Zoetis (ZTS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in th
Our Top 10 Picks For Dividend Growth Stocks - July 2023
09:00am, Saturday, 22'nd Jul 2023
This monthly series of articles focuses on DGI stocks that are likely to provide a high rate of dividend growth rather than a high current yield. We use our proprietary models to rate quantitatively a
Zoetis: My Dog Approves Of This Dividend Compounder
10:28am, Wednesday, 19'th Jul 2023
Zoetis: My Dog Approves Of This Dividend Compounder
2 Dividend Stocks That Doubled Their Payouts in 5 Years
05:27am, Wednesday, 19'th Jul 2023
Zoetis and Mastercard don't offer high yields, but both aggressively raised their payouts in recent years. Both companies have modest payout ratios, suggesting more hikes could be on the way.
